Drug Trial Radar · NCT05815758
Evaluation of the Safety and Pharmacokinetics of Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Combination Ophthalmic Solution
Last checked: Nov 19, 2026Latest source record: Jul 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
512
Actual
Start
Apr 20, 2023
Primary completion
Sep 18, 2023
Study completion Sep 18, 2023
Sponsor
- Lead sponsor
- Bausch & Lomb IncorporatedIndustry
- Sponsor type
- Industry
- First posted
- Apr 18, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 5 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
To compare the safety and tolerability of brimonidine tartrate 0.025%/ketotifen fumarate 0.035% combination ophthalmic solution versus its vehicle in healthy adult subjects and in pediatric subjects.
Conditions
- Allergic Conjunctivitis
Interventions
Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Ophthalmic Solution (Combo)Drug
Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Ophthalmic Solution (Combo)
Vehicle of brimonidine tartrate 0.025%/ketotifen fumarate 0.035% ophthalmic solutionDrug
Vehicle of brimonidine tartrate 0.025%/ketotifen fumarate 0.035% ophthalmic solution
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment Emergent Adverse Events (TEAEs)Time frame: Baseline up to Day 42
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
104- Arizona Eye Center
Chandler, Arizona
103- Seidenberg Protzko Eye Associates
Havre de Grace, Maryland
101 - Andover Eye Associates
Andover, Massachusetts
105- NC Eye Associates
Apex, North Carolina
107 Total Eye Care, PA
Memphis, Tennessee
106- Emerson Research Institute, Inc.
Falls Church, Virginia
102 - Piedement Eye Center
Lynchburg, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.